Brain Pharm: Brain Pharmacology Database User: Public
SenseLab  Home Data Search Schema Login	[Data] Pathological mechanism Name Glutamatergic synaptic depression by synthetic amyloid beta-peptide in the medial septum. Description Hypothesis Extracelular pathological element β-Amyloid   show other Intracelular pathological element Pathological action Reduces   show other Process Glutamatergic Synapse Activity   show other Process action Transmitter(s) Glutamate   show other Receptor(s) Muscarinic   show other Channel(s) I L high threshold   show other Pharmacological Agent Pirenzepine   show other Atropine   show other Calcicludine   show other Pharmacological Action Blocks   show other Brain region Neuron Cell model Brain slice preparations   show other Cellular compartment PubMed ID 17171714 Citation AlzWeb Notes Glutamatergic synaptic depression by synthetic amyloid beta-peptide in the medial septum.Santos-Torres J, Fuente A, Criado JM, Riolobos AS, Heredia M, Yajeya J. BetaA effect was blocked by calcicludine (50 nM), a selective antagonist of L-type calcium channels, and also by blocking muscarinic receptors with atropine (5 muM) or pirenzepine (1 microM), a more specific M1-receptor blocker. Pathology Stage Question Claim Other categories referring to "Glutamatergic synaptic depression by synthetic amyloid beta-peptide in the medial septum."   Revisions: 3 Last time: 11/21/2008 10:47:46 AM Reviewer: Pradeep Mutalik Owner: Pradeep Mutalik
	Questions, comments, problems? Email the Database Administrator This site is Copyright 2010, Yale Center for Medical Informatics